Founded in 2020, iTolerance is regenerative medicine company developing a potential cure for Type 1 Diabetes that eliminates the need for chronic immunosuppression of patients.
The company’s lead program, ITOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 Diabetes. As an adjunct therapy with pancreatic islet cells, the company says that ITOL-101 creates a durable, localized immune tolerance that has the potential to protect implanted islet cells from rejection by the body’s own immune system. This localized immune acceptance potentially eliminates the need for sustained immunosuppressants and allows for localized remodeling and functional engraftment. iTolerance reports that ITOL-101 has demonstrated compelling efficacy in non-human primate studies. The company plans to advance ITOL-101 towards an IND and first-in-man study.
In addition to ITOL-101, iTolerance is advancing its regenerative cell therapy platform to fuel a ‘robust’ pipeline addressing other high-value indications.
Founded in 2020, Regain Therapeutics is pursuing a new treatment approach for Alzheimer's disease which focuses on replenishing soluble amyloid-beta peptides in the brain rather …
Ancilia Biosciences develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. The company …
Kanvas Bioscience wants to revolutionize microbial research and infectious disease diagnostics with next generation imaging technology that is able to provide deeper information on the …
Bo InnoHealth is a spin-off from the Hong Kong Polytechnic University developing a novel microencapsulation technology which can protect probiotics and probiotics and enable their …
Talus Bio aims to revolutionize drug development for gene regulators by enabling the ability to study gene regulatory proteins (GRPs) in a living cell environment. …
